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Background: Owing to the limited validity of clinical data on the treatment of prostate cancer (PCa) and bone metastases,
biochemical markers are a promising tool for predicting survival, disease progression and skeletal-related events (SREs) in these
patients. The aim of this study was to evaluate the predictive capacity of biochemical markers of bone turnover for mortality risk,
disease progression and SREs in patients with PCa and bone metastases undergoing treatment with zoledronic acid (ZA).
Methods: This was an observational, prospective and multicenter study in which ninety-eight patients were included. Patients
were treated with ZA (4mg every 4 weeks for 18 months). Data were collected at baseline and 3, 6, 9, 12, 15 and 18 months after
the beginning of treatment. Serum levels of bone alkaline phosphtase (BALP), aminoterminal propeptide of procollagen type I
(P1NP) and beta-isomer of carboxiterminal telopeptide of collagen I (b-CTX) were analysed at all points in the study. Data on
disease progression, SREs development and survival were recorded.
Results: Cox regression models with clinical data and bone markers showed that the levels of the three markers studied were
predictive of survival time, with b-CTX being especially powerful, in which a lack of normalisation in visit 1 (3 months after the
beginning of treatment) showed a 6.3-times more risk for death than in normalised patients. Levels of these markers were also
predictive for SREs, although in this case BALP and P1NP proved to be better predictors. We did not find any relationship
between bone markers and disease progression.
Conclusion: In patients with PCa and bone metastases treated with ZA, b-CTX and P1NP can be considered suitable predictors for
mortality risk, while BALP and P1NP are appropriate for SREs. The levels of these biomarkers 3 months after the beginning of
treatment are especially important.
Metastases are the most deadly events in the progression of cancer
and are commonly associated with poor prognosis. The skeleton is
one of the most common organs to be affected by metastatic
cancers. One such cancer is prostate cancer (PCa). Patients with
bone metastases have a high degree of morbidity and present with
severe pain and high incidence of hypercalcemia, spinal cord
compression and pathological fractures. These skeletal-related
events (SREs) lead to a reduction in the quality of life and survival
rate and constitute an important public-health problem (Coleman,
1997; Mundy, 2002).
Depending on the primary tumour, bone metastases can be
either lytic or blastic with respect to bone. Tumoral cells release
factors that activate osteoclasts or osteoblasts. PCa bone metastases
are blastic in nature. Our body compensates for the increase of bone
resorption or formation by increasing bone formation or resorp-
tion, respectively, by means of the coupling phenomenon. Owing to
this fact, patients with bone metastases present a higher degree of
bone remodelling than healthy individuals, thereby making bone
remodelling a useful indicator when diagnosing bone metastases.
Biochemical markers of bone turnover (formation or resorp-
tion) are substances present in serum or urine that allow us to
measure the activity of osteoblasts and osteoclasts. These
characteristics could make these markers useful tools in quantify-
ing the degree of alteration of bone remodelling in the presence of
bone metastases. Bisphosphonates, compounds that directly
produce osteoclastic inhibition, have been used in the treatment
of patients with bone metastases because they reduce the increase
in osteoclastic activity produced by the presence of such
metastases. Bisphosphonates are useful in the case of blastic or
lytic metastases, due to the coupling phenomenon. The decrease in
bone resorption and the concomitant decrease in bone formation
lead to a decrease in the release of factors that also decrease
metastatic growth (Buijs and Pluijm, 2009; Coleman et al, 2010).
All commercial bisphosphonates have been used to treat bone
metastases, but zoledronic acid (ZA) is currently the preferred
option due to its great potency and its ability to be administered
less frequently (Polascik and Mouraviev, 2008). Zoledronic acid
administration produces a significant decrease in bone remodelling
in patients with bone metastases.
Bone scintigraphy is commonly used to assess the extent of
bone metastases; its use is limited in monitoring of treatment
efficacy because it is an expensive, time-consuming technique.
Moreover, scintigraphy presents sensitivity but lacks specificity,
primarily due to slow detectable changes, and the confounding
appearance of lesions containing mixed and/or osteosclerotic
areas (Cook and Fogelman, 2000). For this reason, it would be of
great interest to have biochemical markers that could accurately
predict bone metastases and allow for effective follow-up of the
progress of disease. Biochemical markers of bone turnover may
meet this need.
Previous studies suggest that the levels of bone markers are
correlated with the presence, extent and progression of bone
metastases, including SREs, disease progression and death
(Leeming et al, 2006; Lipton et al, 2007; Lein et al, 2007).
However, more studies are necessary in order to obtain more
definitive conclusions.
The aim of this work was to study the levels of two biochemical
markers of bone formation, bone alkaline phosphatase (BALP) and
aminoterminal propeptide of procollagen I (PINP), and one marker
of bone resorption, beta-isomer of carboxiterminal telopeptide of
collagen I (beta-CTX), in a population of patients with PCa and
bone metastases. Markers were studied in basal conditions and 3, 6,
9, 12, 15 and 18 months after the beginning of treatment with ZA,
and their relationship with mortality, disease progression and SREs
was analysed. Prostatic-specific antigen (PSA) levels and their
correlation with bone markers were also analysed.
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MATERIALS AND METHODS
Study group. The TUGAMO (‘Tumores UroGenitales Avanzados,
Meta´stasis O´seas’, advanced urogenital tumours, bone metastases)
was an observational, prospective and national multicenter study
(n¼ 40 centres) performed in patients with prostate, renal cells and
bladder cancer with bone metastases. This manuscript studies a
subgroup of these patients with PCa. Male patients X18 years old
with histologically confirmed PCa with at least one diagnosed
bone-lesion confirmed by bone scintigraphy were enrolled.
Patients were excluded from the study if they presented with
concomitant pathologies that could interfere in the evaluation of
biochemical markers of bone turnover such as bone metabolic
disorders, Paget’s disease of bone, hyperparathyroidism, thyroid
abnormalities, abnormal intestinal absorption or hepatic or renal
alterations. Patients treated with bisphosphonates prior to their
inclusion in the study and with dental infection and diagnosis of
mandibular osteonecrosis were also excluded.
Ninety-eight patients with PCa and bone metastases were
included in the study. Sixty had previously received hormonal
treatment and 38 had received no prior treatment. Once
ZA treatment was established, none of the patient received
hormonal treatment. Table 1 shows the demographics and baseline
disease characteristics of the patients studied.
A follow-up of the patients was performed over 18 months.
Baseline values (visit 0, v0) were those obtained when a patient
initiated treatment with ZA (Zometa, Novartis Pharma, Basel,
Switzerland), 4mg every 4 weeks over 18 months. During the
study, administration of medication and standard antineoplasic
therapies, including cytotoxic chemotherapy agents were also
allowed. Data were collected at v0, v1 (3 months), v2 (6 months), v3
(9 months), v4 (12 months), v5 (15 months) and v6 (18 months).
The definition of SREs included pathological fractures, severe pain,
hypercalcemia and spinal cord compression. Patients were also
evaluated for disease progression by physical examination,
including evaluation of ECOG performance and ECOG pain score.
This study was approved by the Ethics Committee of the Unitat
d´Avaluacio´, Suport I Prevencio´ of Clinical Hospital of Barcelona
(Spain). Informed consent was obtained from each patient before
the study began.
Markers evaluation. Bone alkaline phosphatase was determined
by ELISA (IDS, Boldon, UK). Inter- and intra-assay coefficients of
variation of the method were o6.4% and o4.5%. Sensitivity was
0.7 mg l 1. The normal range for healthy adult men was p15 mg/l.
PINP was determined by electrochemiluminiscence (Elecsys,
Roche, Mannheim, Germany). Inter- and intra-assay coefficients
of variation of the method were 3.7% and 2.9%. Sensitivity was
5 ngml 1. Normal range for healthy adult men wasp62 ngml 1.
Beta-isomer of carboxiterminal telopeptide of collagen I was
determined by electrochemiluminiscence (Elecsys, Roche). Inter-
and intra-assay coefficients of variation of the method were 4.7%
and 4.6%. Sensitivity was 0.070 ngml 1. The normal range for
healthy adult men was p0548 ngml 1.
Prostatic-specific antigen was determined by electrochemilumi-
niscence (Elecsys, Roche). Inter- and intra-assay coefficients of
variation of the method wereo0.46% and o2.5%. Sensitivity was
0.03 ngml 1. The normal range for healthy adult men was
p4 ngml 1.
Statistical analyses. Bone markers were summarised in terms of
mean, s.d., median and quartiles. Absolute and relative changes in
bone markers as compared with baseline and previous visit were
assessed at each visit. Absolute changes were summarised by mean
and s.d. and their statistical significance was assessed by Wilcoxon
test for paired samples. Relative changes were converted to
logarithms and summarised by geometric mean and s.d. Their
statistical significance was assessed using the Student’s t-test for
paired samples.
Receiver operating characteristic (ROC) analysis were per-
formed to evaluate the predictive capability of bone markers levels
for mortality, SREs and progression, obtaining the cutoff point that
maximises sensitivity and specificity. Receiver operating character-
istic curves were performed (1) with the baseline bone markers
levels and (2) with changes in bone markers in v1 with respect to v0
(defined as marker in v1/marker in v0). Then, survival curves were
constructed using the Kaplan–Meier method by taking into
account four classifications, and comparisons were performed
using the log-rank test:
1. Biomarker ‘higher than’ or ‘equal to or lesser than’ the upper
limit of normality.
2. Basal biomarker ‘higher’ or ‘equal to or lesser than’ than the
‘cutoff’ obtained from the ROC curves of basal values against
death, SREs appearance or disease progression.
3. Biomarker value in v1/biomarker in v0 ‘higher’ or ‘equal to or
lesser than’ the cutoff obtained from the corresponding ROC
curves.
4. Normal or non-normal level of bone markers at v1.
Finally, Cox regression models were fitted to quantify the degree
of association between potential predictors and mortality, the
occurrence of SREs and progression. The models were summarised
by hazard ratio estimate, s.e. and 95% confidence interval (CI) for
hazard ratio. Also the P-value from hypothesis testing of the
hazard ratio was shown.
We estimated the size of the hazard ratios in order that the
study could present a statistical power of 80%. For this purpose,
hazard ratios magnitudes, accumulated incidence of the study
event (death, progression or SREs) and size of the compared
groups were considered. According to these considerations, the
hazard ratios that could detect results with a potency of 80% were
42.7 for death, 41.9 for progression and 42.5 for EREs
appearance. The significance level was set at 0.05 for all tests.
Table 1. Patients demographics and baseline disease characteristics
Variable
Mean age (years) 71.9±8.4
Weight (kg) 77.5±15.1
Primary therapy n (%)
None 35 (37%)
Hormonal therapy 60 (63%)
Prior skeletal-related events n (%)
No 93
Yes 2
Soloway classification n (%)
o6 Bone metastases 42 (44.2%)
6–20 Bone metastases 30 (31.6%)
420 Bone metastases 11 (11.6%)
Super scan 12 (12.1%)
Time from bone metastases diagnosis (months) 1.8±2.1
BALP (mg l 1) 125±215
P1NP (ngml1) 393±766
b-CTX (ngml1) 0.930±1.113
Ninety-eight patients with PCa and bone metastases.
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RESULTS
Bone markers and PSA levels at baseline and after treatment
with ZA. The concentrations of bone markers did not differ
significantly between the groups of patients with hormonal therapy
and without previous hormonal treatment both in basal conditions
and after treatment with ZA. Thus, all subsequent calculations
were performed with the data obtained from all patients in the
respective groups.
At baseline, patients with PCa and bone metastases exhibited
elevated levels of bone markers, and a significant correlation was
found between values obtained from markers and Soloway
classification (Soloway et al, 1998), (Tables 1 and 2).
Table 3 shows the percentages of patients with pathological
levels of bone markers throughout the study. Zoledronic acid
treatment produced a gradual increase of the percentage of patients
with normal values of biomarkers. Beta-isomer of carboxiterminal
telopeptide of collagen I is the marker that experienced the highest
degree of normalisation, with 93.3% of patients exhibiting normal
levels after 18 months of ZA treatment.
Table 4 shows the mean values of biochemical markers of bone
turnover throughout the study. Levels of markers tended to
decrease significantly until v2 visit. From this point, no significant
change was observed. As expected, levels of PSA in patients with
previous hormonal treatment were lower than in those without
previous treatment (mean value: 5.9 ngml 1, 95% CI: 3.0–11.6 vs
64.4 ngml 1, 95% CI: 29.7–139.9, Po0.01). After ZA treatment,
values of PSA of previously untreated patients decreased
significantly to the levels of treated patients (mean value:
7.80 ngml 1 vs 2.03 ngml 1), without significant differences
between the two groups (Po0.09) and without significant
differences along the whole period of the study (Po0.47). Levels
of bone markers correlated positively with PSA values at baseline
(Po0.001 for the three studied markers) and at visits 1, 2, 3, 4 and
5 (Po0.001 for BALP, Po0.01 for P1NP and Po0.05 for b-CTX).
However, at visits 6 and 7, only values of BALP correlated with
PSA levels (Po0.01).
Global survival, defined as time between the beginning of
treatment and death during the 18 months of treatment showed a
mean value of 16.3 months. Ninety-eight patients started the study
and 57 completed it. Losses of participants were due to death (21),
failure to provide informed consent (4), loss to follow-up (7),
clinical criteria (5) and others (changes of address, renal
insufficiency, etc. (4)).
Capability of bone biomarkers to predict mortality. With
respect to mortality, using the first categorisation explained in
Materials and Methods (biomarker ‘higher than’ or ‘equal to or
lesser than’ the upper limit of normality), no significant differences
were obtained in the Kaplan–Meier curves plotting survival time
(data not shown). However, Kaplan–Meier analysis distinctly
demonstrated different survival curves for the three bone markers
studied, according to the second (basal biomarker ‘higher’ or ‘equal
to or lesser than’ than the ‘cutoff’ obtained from the ROC curves of
basal values against death) (Figure 1), the third (biomarker value in
v1/biomarker in v0 ‘higher’ or ‘equal to or lesser than’ the cutoff
obtained from the corresponding ROC curves) (Figure 2A) and the
fourth (normal or non-normal level of bone markers at v1)
classifications (Figure 2B). Tables 5 and 6 show the univariate Cox
regression analysis derived from the above mentioned Kaplan–
Meier curves. The hazard ratio indicates how many times greater
the risk of death was in the given group relative to the other group.
The three markers studied could be useful as predictors of survival,
although b-CTX levels in v1 were especially significant in this
regard. Our results show that values of b-CTX were especially
relevant for survival during the 18 months of ZA treatment. A
value of v1/v040.4 (a decrease of b-CTX in v1 of o40%) and/or
lack of normality in levels of b-CTX, indicates a six-fold increase in
risk of mortality along the study. Similar behaviour, although with
minor statistical potency presents P1NP values. A decrease of
P1NP in v1 ofo44% and/or lack of normality, indicates a five-fold
increase in the risk of mortality, and no changes in levels of BALP
between v0 and v1 indicates an increase of three-fold in the risk of
mortality.
Table 2. Correlation between bone markers and Soloway classification
N
BALP
lg l1 N
P1NP
ngml1 N
b-CTX
ngml1
o6 Bone
metastases
37 29±34 38 78±138 38 0.439±0.500
6–20 Bone
metastases
28 122±177 28 299±347 27 0.925±1.068
420 Bone
metastases
8 287±271 10 790±347 10 1.544±1.364
Super scan 10 362±378 11 1361±1653 11 2.083±1.485
Pa — o0.001 — o0.001 — 0.0007
Patients with PCa and bone metastases.
aKruskal–Wallis.
Table 3. Percentages of patients with pathological levels of biochemical
markers of bone turnover along the study
Visit V0 V1 V2 V3 V4 V5 V6
Numbers of patients 98 95 87 77 66 58 57
Marker BALP: elevated 74.7 58.6 54.4 40.9 50.0 40.0 43.3
Marker P1NP: elevated 58.9 39.4 31.6 15.9 17.1 18.4 20.0
Marker b-CTX:
elevated
47.9 31.0 17.5 11.4 10.0 7.9 6.7
Abbreviations: b-CTX¼ b-isomer of carboxiterminal telopeptide of collagen I; BALP¼bone
alkaline phosphatase; P1NP¼ aminoterminal propeptide of procollagen I. Ninety-eight
patients with PCa and bone metastases treated with zoledronic acid (4mg every 4 weeks)
during 18 months. V0: basal visit; V1, V2, V3, V4, V5 and V6: visits after 3, 6, 9, 12, 15 and 18
months, respectively, following the beginning of the treatment. Values are expressed as
percentages with respect to the total numbers of patients in each visit.
Table 4. Levels of biochemical markers of bone turnover throughout the
study
Visit
Numbers of
patients BAP (lg l1)
P1NP
(ngml1) b-CTX (ngml1)
V0 98 126.7±208.8 399±741 0.967±1.094
a
V1 95 52.7±74.4
a 157±253a 0.456±0.612a
V2 87 35.3±62.9
a,b 110±224a,b 0.308±0.384a
V3 77 38.6±80.0
a 71±139a 0.255±0.354a
V4 66 35.3±57.5
a,c 52±77.0a 0.209±0.255a
V5 58 31.2±49.6
a 55±146a 0.216±0.267a,c,e
V6 57 26.0±33.9
a,c,d 47±74a,c,f 0.235±0.252a,b,c,d,e
Abbreviations: b-CTX¼ b-isomer of carboxiterminal telopeptide of collagen I; BALP¼bone
alkaline phosphatase; P1NP¼ aminoterminal propeptide of procollagen I. Ninety-eight
patients with Pca and bone metastasis treated with zoledronic acid (4mg every 4 weeks)
during 18 months. V0: basal visit; V1, V2, V3, V4, V5 and V6: visits after 3, 6, 9, 12, 15 and 18
months, respectively, following the beginning of the treatment. Values are expressed as
mean±s.d. Statistical significance, P-values of Student’s t-test: ao0.001 vs V0; bo 0.005 vs
V1; c o 0.05 vs V2; d o 0.05 vs V3; e o 0.01 vs V4; f o 0.01 vs V5.
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Bone biomarkers and disease progression. Distinctly than in the
case of mortality, we did not find any association between bone
marker levels and disease progression. Basal levels of bone
biomarkers did not show any correlation with disease progression
through Kaplan–Meier curves analysis. Normalisation of bone
marker levels after ZA treatment or v1/v0 marker levels ratio also
failed to show any statistically significant association with disease
progression. As we did not find any significant differences in
Kaplan–Meier curves, Cox regression analysis was not performed.
Capability of bone biomarkers to predict SREs appearance. In
the present work, two patients presented with SREs before the
beginning of the study. Seven, 7, 5, 3, 2 and 2 new SREs were
observed in v1, v2, v3, v4, v5 and v6 respectively. With respect to
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Figure 1. Kaplan–Meier analysis of overall survival after the completion of treatment with zoledronic acid according to basal levels of
biomarkers. Stratification was performed using the cutoff points obtained from the ROC curves of ‘basal values of biomarkers at the beginning of
the study’ against death: (A) BALP, bone alkaline phosphatase. The cutoff point obtained in the ROC curve was 164.7mg l1; (B) PINP,
aminoterminal propeptide of procollagen I. The cutoff point obtained in the ROC curve was 148.5 hg/ml; (C) b-CTX, b-isomer of carboxiterminal
telopeptide of collagen. The cut-off point obtained in the ROC curve was 1.1 ngml 1.
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Figure 2. (A) Kaplan–Meier analysis of overall survival after the completion of treatment with zoledronic acid according to the ratio ‘level of
biomarker in v1/ level of biomarker in v0’, for P1NP and b-CTX. The stratification was performed using the cutoff points obtained from the ROC
curves of ‘changes in bone markers in v1 with respect to v0’ against death. The cutoff point obtained in these ROC curves were 0.442 for PINP and
0.4 for b-CTX. (B) Kaplan–Meier analysis of overall survival after the completion of treatment with zoledronic acid according to the dichotomous
criterion of achievement or not of a normal level of bone markers in the v1 for P1NP and b-CTX. *Values of biomarkers into the normal range are
indicated in Materials and Methods. Kaplan–Meier curve of BALP is not presented because differences between groups according to these criteria
were not statistically significant.
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SREs appearance, Figure 3A and B show the relevant results.
Tables 7 and 8 shows the univariate Cox regression analysis of
Kaplan–Meier curves related to SREs development. In this case,
values of the three markers were closely related to the SREs, and
specially BALP, in which a rate in the values of v1/v0 of BALP that
was higher than 0.873 was associated with a probability of SREs
development 4.07-times higher, while a lack of normalisation in
P1NP after treatment increased the probably of SREs appearance
3.8 times.
It is important to point that all the values of hazard ratios that
presented a statistical significance in the study, presented values
higher than those considered to have a minimum of 80% of
statistical power (see Materials and Methods).
DISCUSSION
As higher levels of PSA are found with more advanced stages of
PCa and with worse outcomes, PSA has been historically used as a
staging and prognostic tool (Shariat et al, 2004). However, PSA is
now commonly regarded as an indicator of prostate volume and is
not independently diagnostic or prognostic in PCa. Owing to these
limitations, there is an urgent need for new prognostic biomarkers
to enhance the clinical management of PCa. This could be
denominated the post-PSA era (Bickers et al, 2009).
To perform this work, we selected two biochemical markers of
bone formation – BALP and P1NP – and one of bone resorption –
b-CTX. Of these, BALP has high specificity, as it is a product only
released by the active osteoblast and has demonstrated a great
sensitivity for detecting increases in bone turnover (Garnero and
Delmas, 1993). Its weakness, however, is that monoclonal
antibodies against BALP exhibit a cross-reactivity of 15% with
hepatic isoenzyme (Garnero and Delmas, 1993). As a result, values
can be abnormally elevated in the presence of hepatic diseases.
However, in our work, none of the PCa patients with bone
metastases presented simultaneously with hepatic metastases.
Thus, no interference of hepatic on bone isoenzyme was present.
Aminoterminal propeptide of procollagen type I and b-CTX have
been recently recommended by the International Osteoporosis
Foundation and the International Federation of Clinical Chemistry
and Laboratory Medicine as reference markers in all clinical studies
(Vasikaran et al, 2011).
In a first stage, biomarkers of bone formation and bone
resorption were evaluated for their ability to act as useful tools for
the diagnosis of bone metastases (Coleman, 1997; Leeming et al,
2006; Huang and Ouyang, 2012). All biomarkers were indicative of
skeletal involvement, albeit with different sensitivity. In previous
works, one group of authors of the present work found a sensitivity
of 87.5% and a specificity of 100% for BALP (430 ngml 1) in
the detection of bone metastases in PCa (Lorente et al, 1996), the
values of BALP being more efficient than PSA levels in the
prediction of positive bone scans. De la Piedra et al (2003) found a
specificity and sensitivity of 100% in the levels of P1NP and
b-CTX. This high sensitivity and specificity was due to the fact that
this is the only work in the literature in which all PCa patients were
studied before any treatment was initiated. In the present work,
the patients showed elevated baseline levels of BALP, P1NP and
b-CTX. Brasso et al (2006) also found an elevation in these
markers. The increase in the levels of bone formation at the onset
of skeletal metastases reflects the dominant osteoblastic element of
the bone remodelling process in these patients, although due to the
coupling remodelling phenomena, markers of bone resorption are
also elevated. This fact produces a high correlation between
markers, as we found in the present work. The fact that bone
metastases produce an increase in remodelling is corroborated by
the correlation between bone markers levels and Soloway
classification, as described in the present and previous works
(Coleman, 1997; Leeming et al, 2006).
Although hormonal treatment tends to produce an increase in
the levels of biochemical markers of bone turnover (Smith et al,
2004) (a tendency to higher values was observed in treated
patients), in basal conditions, the concentration of bone markers
did not differ significantly between patients with and without
hormonal treatment. After ZA treatment, values of all markers
decreased and values of bone markers of treated and untreated
groups of patients were quite similar. This is the reason for which
we performed all the subsequent calculations with the data
obtained from all patients in the study group.
Owing to the antiosteoclastic action of ZA, the first effect
observed after ZA treatment was the significant decrease in
bone markers. The highest degree of normalisation was observed in
Table 5. Univariate Cox regression analysis of bone markers for survival
prediction after 18 months of ZA treatment
Marker Hazard ratio s.d. 95% CI P-value
BALP
V0 elevated
a 1.469 0.9423 0.418–5.164 0.5485
V04164.7
b 3.157 1.7406 1.071–9.302 0.0371
V1/V041.006
c 3.048 2.2604 0.713–13.039 0.1328
P1NP
V0 elevated
a 1.564 0.7847 0.585–4.181 0.3722
V04148.5
b 3.372 1.6162 1.318–8.627 0.0112
V1/V040.442
c 4.969 3.4755 1.261–19.573 0.0219
b-CTX
V0 elevated
a 2.318 1.1262 0.894–6.007 0.0837
V041.1
b 2.954 1.4138 1.156–7.547 0.0237
V1/V040.4
c 6.100 4.8328 1.291–28.820 0.0224
Abbreviations: b-CTX¼b-isomer of carboxiterminal telopeptide of collagen I; BALP¼bone
alkaline phosphatase; P1NP¼ aminoterminal propeptide of procollagen I. Ninety-eight
patients with PCa and bone metastases treated with zoledronic acid (4mg every 4 weeks)
during 18 months. V0: basal visit; V1: visit after 3 months following the beginning of the
treatment.
aBiomarker ‘higher than’ the upper limit of normality.
bBiomarker ‘higher than’ the cut-off obtained from the ROC curves of basal values against
death.
cBiomarker value in v1/biomarker in v0 ‘higher than the cut-off obtained from the
corresponding ROC curves.
Table 6. Univariate Cox regression analysis of bone markers for survival
prediction according to normalisation in V1
Marker Hazard ratio s.d. 95% CI P-value
BALP
No normalisationa 2.029 1.4867 0.483–8.530 0.3341
P1NP
No normalisationa 5.053 3.3285 1.389–18.376 0.0139
b-CTX
No normalisationa 6.271 4.0944 1.744–22.548 0.0049
Abbreviations: b-CTX¼b-isomer of carboxiterminal telopeptide of collagen I; BALP¼bone
alkaline phosphatase; P1NP¼ aminoterminal propeptide of procollagen I. Ninety-eight
patients with PCa and bone metastases treated with zoledronic acid (4mg every 4 weeks).
V1: visit after 3 months following the beginning of the treatment.
aValue of biomarker in the V1 higher than the upper limit of normality.
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b-CTX, presenting a 93.3% of the patients normal values of this
marker after 18 months of treatment.
Our results show that values of b-CTX were especially relevant
for the prediction of survival during the 18 months of ZA
treatment. A decrease of b-CTX in v1 of o40% and/or lack of
normality in levels of b-CTX, indicates a six-fold increase in the
risk of mortality along the study. Similarly, a decrease of P1NP in
v1 ofo44% and/or lack of normality, indicates a five-fold increase
in the risk of mortality, and no changes in levels of BALP between
v0 and v1 indicates an increase of three-fold in the risk of mortality.
In agreement with our results, Jung et al (2011) found that P1NP
and cross-linked carboxiterminal telopeptides of collagen I (ICTP)
could be considered suitable predictors for survival in patients with
PCa and bone metastases. Brasso et al (2006) found that patients
with elevated serum P1NP, BAP and CTX at the time of diagnosis
of metastatic PCa had significantly lower rates of survival than
patients with normal levels of these biomarkers.
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Figure 3. (A) Kaplan–Meier analysis for the appearance of SREs after the completion of treatment with zoledronic acid according to the ratio
‘level of biomarker in v1/ level of biomarker in v0’, for BALP, P1NP and b-CTX. The stratification was performed using the cutoff points obtained
from the ROC curves of ‘changes in bone markers in v1 with respect to v0’ against SREs appearance. The cutoff points obtained in the ROC
curves were 0.873 for BALP, 0.778 for P1NP and 0.539 for b-CTX. (B) Kaplan–Meier analysis for the appearance of SREs after the completion of
treatment (18 months) with ZA according to the dichotomous criterion of achievement or not a normal level of bone markers in the v1 for P1NP
and b-CTX. *Values of biomarkers into the normal range are indicated in Materials and Methods. Kaplan–Meier curve of BALP is not
presented because differences between groups according to these criteria were not statistically significant.
Table 7. Univariate Cox regressing analysis of bone markers for SRES
prediction after completion of ZA treatment
Marker Hazard ratio s.d. 95% CI P-value
BALP
V0 elevated
a 0.796 0.3649 0.324–1.955 0.6192
V0478.4
b 2.052 0.8987 0.870–4.841 0.1008
V1/V040.873
c 4.068 2.1641 1.434–11.540 0.0083
P1NP
V0 elevated
a 1.469 0.6441 0.622–3.469 0.3801
V04135.6
b 1.993 0.8395 0.873–4.551 0.1016
V1/V0 40.778
c 2.905 1.4521 1.0917.738 0.0329
b-CTX
V0 elevated
a 2.303 0.9881 0.993–5.340 0.0519
V040.584
b 2.006 0.8468 0.877–4.588 0.0991
V1/V040.539
c 3.435 1.7529 1.263–9.339 0.0156
Abbreviations: b-CTX¼b-isomer of carboxiterminal telopeptide of collagen I; BALP¼bone
alkaline phosphatase; P1NP¼ aminoterminal propeptide of procollagen I. Ninety-eight
patients with PCa and bone metastases treated with zoledronic acid (4mg every 4 weeks).
V0: basal visit; V1: visit after 3 months following the beginning of the treatment.
aBiomarker ‘higher than’ the upper limit of normality.
bBiomarker ‘higher than’ the cut-off obtained from the ROC curves of basal values against
SREs appearance.
cBiomarker value in v1/biomarker in v0 ‘higher than the cut-off obtained from the
corresponding ROC curves.
Table 8. Univariate Cox regression analysis of bone markers for SRES
prediction according to normalisation of values of bone markers at V1
Marker Hazard ratio s.d. 95% CI P-value
BALP
No normalisationa 0.972 0.5056 0.351–2.694 0.9571
P1NP
No normalisationa 2.900 1.4720 1.073–7.843 0.0359
b-CTX
No normalisationa 3.847 1.9443 1.42810.359 0.0077
Abbreviations: b-CTX¼ b-isomer of carboxiterminal telopeptide of collagen I; BALP¼bone
alkaline phosphatase; P1NP¼ aminoterminal propeptide of procollagen I. Ninety-eight
patients with PCa and bone metastases treated with zoledronic acid (4mg every 4 weeks)
during 18 months. V1: visit after 3 months following the beginning of the treatment.
aValue of biomarker in the V1 higher than the upper limit of normality.
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In the present work, we did not find any association between
bone markers and disease progression. This result is consistent
with that of Mountzios et al (2010), who found that none of the
bone markers were able to predict clinical outcomes. Santini et al
(2006) also found a very limited impact of b-CTX levels on the
detection of disease progression.
With respect to survival prediction, the three bone markers were
suitable predictors for SREs appearance, with BALP and P1NP
being the most potent. In this case, a value of v1/v040.873 in BALP
(a decrease of BALP in v1 ofo87%) indicates a four-fold increase
in the risk of SREs. The specific osteoblastic – and in consequence
osseous – nature of BALP and P1NP could be the reason behind
the close association between high bone formation levels and SREs,
as compared with b-CTX. Lein et al (2009) found that in PCa
patients treated with ZA, a decrease of P1NP below 25% was
predictive for SREs development.
CONCLUSIONS
In conclusion, use of bone markers and especially of b-CTX, in the
follow-up of patients with PCa and bone metastases improved
prediction of the disease development, complementing predictions
based exclusively on clinical data. The decrease in b-CTX following
the first administration of ZA is closely correlated with survival,
while the decrease in BALP and P1NP is a strong predictor of the
appearance of SREs. Use of these three biomarkers provides an
interesting advantage, not only for clinicians regarding clinical
decisions, but also for patients regarding their own decisions on
treatment planning.
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